Evidence map›Paper›PMID 34950509›Full record

ReviewCardiac failure review2021

Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure.

Marko Kumric, Tina Ticinovic Kurir, Josko Bozic, Duska Glavas, Tina Saric, Bjørnar Marcelius, Domenico D'Amario, Josip A Borovac

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiac failure review, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06244693 (Description and Analysis of Congestion During Hospitalization for Acute Decompensated Heart Failure), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06244693 completednot on this mapstarted 2024, after this paper: background citation

Description and Analysis of Congestion During Hospitalization for Acute Decompensated Heart Failure

Typeobservational_patient_registrySponsorUniversity of ChileRan2024 to 2026Enrolled49ConditionsHeart Failure, CongestionArmsNo intervention
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Characterizing the molecular landscape of venous congestion.World journal of critical care medicine · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Marko KumricDepartment of Pathophysiology, University of Split School of Medicine Split, Croatia.
Tina Ticinovic KurirDepartment of Pathophysiology, University of Split School of Medicine Split, Croatia.
Josko BozicDepartment of Pathophysiology, University of Split School of Medicine Split, Croatia.
Duska GlavasClinic for Heart and Vascular Diseases, University Hospital of Split Split, Croatia.
Tina SaricInstitute of Emergency Medicine of Split-Dalmatia County Split, Croatia.
Bjørnar MarceliusDepartment of Pathophysiology, University of Split School of Medicine Split, Croatia.
Domenico D'AmarioDepartment of Cardiovascular and Thoracic Sciences, Fondazione Policlinico A Gemelli IRCCS Rome, Italy.
Josip A BorovacDepartment of Pathophysiology, University of Split School of Medicine Split, Croatia.
University of Split · HRCroatian Hydrographic Institute · HRUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because heart failure (HF) is more lethal than some of the common malignancies in the general population, such as prostate cancer in men and breast cancer in women, there is a need for a cost-effective prognostic biomarker in HF beyond natriuretic peptides, especially concerning congestion, the most common reason for the hospitalisation of patients with worsening of HF. Furthermore, despite diuretics being the mainstay of treatment for volume overload in HF patients, no randomised trials have shown the mortality benefits of diuretics in HF patients, and appropriate diuretic titration strategies in this population are unclear. Recently, carbohydrate antigen (CA) 125, a well-established marker of ovarian cancer, emerged as both a prognostic indicator and a guide in tailoring decongestion therapy for patients with HF. Hence, in this review the authors present the molecular background regarding the role of CA125 in HF and address valuable clinical aspects regarding the relationship of CA125 with both prognosis and therapeutic management in HF.

Indexed as

CA125carbohydrate antigencongestiondecompensationheart failureinflammationtailored therapy

Identifiers

PMID34950509
PMCPMC8674624
OpenAlexW4200257019

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.